RYSTIGGO
RYSTIGGO is a prescription medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are acetylcholine receptor (anti-AChR) antibody positive or muscle-specific tyrosine kinase (anti-MuSK) antibody positive.
In gMG, harmful anti-AChR or anti-MuSK antibodies can get in the way of signals between nerves and certain receptors on muscles.
In the neuromuscular junction, where nerves and muscles meet, this loss of signaling can lead to muscle weakness, fatigue, shortness of breath, and other gMG symptoms.
These harmful antibodies can continue to stay in your system because of an immune system protein called FcRn (neonatal Fc receptor).
FcRn can extend the life of certain antibodies, including anti-AChR and anti-MuSK antibodies, by preventing them from being broken down by your cells’ natural waste clearance system.
RYSTIGGO works by specifically targeting FcRn and blocking it from extending the life of these harmful antibodies.
This helps ensure they are broken down in the cell normally.
During a RYSTIGGO treatment cycle, there are fewer harmful antibodies in the way of signaling between nerves and muscles.
Individual results may vary, and not all people will experience improvements.
Prednisone
Prednisone is used to treat many different inflammatory conditions such as arthritis, lupus, psoriasis, ulcerative colitis, allergic disorders, gland (endocrine) disorders, and conditions that affect the skin, eyes, lungs, stomach, nervous system, or blood cells.
IVIG
Intravenous immune globulin (“IVIG”) is a product made up of antibodies that can be given intravenously (through a vein). IVIG is given into a vein (“intravenously”), in an infusion that takes one hour or more. The amount of IVIG you need for each dose depends on your weight as well as the reason you are getting the IVIG:
Plasmapheresis/Apheresis
Plasmapheresis/Apheresis is a process in which the fluid part of the blood, called plasma, is removed from blood cells by a device known as a cell separator. The separator works either by passing the blood at high speed to separate the cells from the fluid or by passing the blood through a membrane with pores so small that only the fluid part of the blood can pass through.
Eculizumab
Eculizumab is the first treatment to be approved to treat adults with anti-AChR Ab+ gMG in more than 60 years. Soliris works to help manage anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis (anti-AChR Ab+ gMG) by focusing on a specific part of your immune system.
VYVGART
VYVGART is the first treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive gMG. VYVGART is a fragment of an IgG antibod
Rituximab
Rituximab is a genetically engineered antibody that depletes CD20+ B-cells and is Food and Drug Administration- approved for treatment of non-Hodgkin lymphoma, CD20+ CLL, and rheumatoid arthritis. It carries a favorable side effects profile.